Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Note

<< Previous

Bullboard Posts

Next >>

Post by Layth1990on Aug 09, 2021 2:01pm

349 Views

Post# 33672731

Note

Anyone who thinks this stock will not recover is wrong. I think it is an opportunity to average down. Don't listen to people like duster or yukon. I have blocked them long time ago but i bet they keep on spaming.

the company has competent people at all levels and i am sure they will figure this out. It is going to take time but it is an easy 3X within a year.

Antibe has been there in 2015 and it happened again. We can clearly see the stock is recovering slowly after investors realized the sell was driven by panic and it is not the end.

cheers and GL for the longs

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing